


Measurement of Galectin-3 and of Suppression of Tumorigenicity 2 in participants at the “Tor des Géants”

C. Le Goff

27/06/2015

ECSS Malmo 2015

Galectin-3



Galectin-3

Stable class II-IV heart failure
at hospital discharge or office consultation
Diagnosis confirmed: $\uparrow$ BNP/NT-proBNP* during course

BLOOD
galectin-3 level

≤ 17.8 ng/mL
Low Risk

Counsel appropriately
Usual care follow-up

>17.8 – 25.9 ng/mL
Moderate Risk

Counsel appropriately
Intensify follow-up
+ Other risk features
→ Intensify medical management
→ Care management


>25.9 ng/mL
High Risk

Counsel appropriately
Monthly or more frequent
follow-up
→ Intensify medical management
→ Care management
→ Advanced strategies


Reassess galectin-3 level in 6 months and follow-up

ST2

ST2: A DECOY RECEPTOR



The « Tor des géants »



Aim of the study

- To examine the evolution of Gal-3 and ST2 in trail runners who ran one of the most challenging ultra-marathons in the world: the Tor des Géants (330 km, altitude range: 2400m).



Methods

- Levels of plasma Gal-3 and ST2 were determined at 4 times:


- before the start
 - after 158km
 - at the end
 - 3 days after the end of the race
- } in 33 trailers




- Samples were directly centrifuged and frozen at -80°C .
- Gal-3 measurement was performed on the VIDAS (Biomerieux) and ST2 was analyzed with the Presage ST2 Assay (Critical Diagnostic).



Results



Results



Discussion

- Correlation between Gal-3 and ST2 ➔ cardiac fibrosis and inflammation.
 - Variation to different degrees.
 - NSAIDs and painkillers.
- ➔ The results of this study demonstrate that this exercise was associated with biochemical abnormalities that may reflect adverse consequences on cardiac structure as fibrosis.

Thank you for your attention

